SAM30001 GSK.

Methods	Study design: cross‐over RCT Duration: 12 weeks Location: 45 centres across the Netherlands
Participants	Population: 77 people with asthma or COPD Baseline characteristics: mean age: NR; male %: intervention group 49%; control group 49%; ethnicity (white %): intervention group 100%; control group 100% Inclusion criteria: age ≥ 12 years with asthma or COPD as diagnosed according to European Respiratory Society criteria Exclusion criteria: NR
Interventions	Treatment arms Salmeterol + fluticasone (single inhaler) Salmeterol (single inhaler) and fluticasone (single inhaler)
Outcomes	Primary outcome: percentage compliance with use of medication
Notes	Funding: GSK Identifier: SAM30001 GSK